CLINICAL TRIALS PROFILE FOR CYCRIN
✉ Email this page to a colleague
All Clinical Trials for CYCRIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00392093 ↗ | Effect of Hormone Replacement Therapy on Lupus Activity | Completed | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 4 | 1997-11-01 | Hypothesis, HRT does not increase the risk of lupus activity exacerbation, it is effective for the relief of menopausal symptoms and improves bone mineral density. Double-blind, randomized, placebo controlled clinical trial. Objectives 1. Determine the effect of HRT on disease activity, menopausal symptoms, bone mineral density, lipid profile, and mammographic parenchymal density in menopausal women with SLE. 2. Determine the incidence rate of major side effects of HRT in menopausal women with SLE. Outcome Measures 1. Primary outcome will be global disease activity throughout the follow-up period. 2. Incidence of lupus flares, time to the first flare, changes in SLEDAI values from baseline at each follow-up visit, maximum disease activity, lupus treatment, hospitalizations, thromboses, and deaths. Menopausal symptoms and depression will be assessed utilizing the Greene Climacteric Scale questionnaire and the Beck Depression Inventory. Bone mineral density of lumbar spine and hip will be performed with dual energy x-ray absorptiometry. In addition, blood and urine samples to measure biochemical markers of bone turnover. Estradiol levels, lipid profile,coagulation tests, cervical cytology examinations, mammography. Inclusion Criteria: (Any two of the following criteria) 1. Amenorrhea of 6 months or more 2. Serum FSH level of 30 IU/L or more 3. Menopausal symptoms 4. Age 48 years or older. Exclusion Criteria: 1. Women older than 65 years 2. Severe lupus activity at baseline 3. Use of estrogens within 3 months of the screening visit 4. Serum creatinine of 2.0 mg/dL or more 5. Hypertriglyceridemia 500 mg/dL or more 6. Metabolic bone diseases 7. Liver disease 8. Untreated hyperthyroidism 9. Recent thrombosis 10. Malignancy 11. Endometrial hyperplasia 12. Undiagnosed uterine bleeding 13. Cervical dysplasia. Subject allocation Random assign, using a computer-generated randomization list to: Conjugated equine estrogens 0.625 mg/day plus 5 mg/day of medroxyprogesterone acetate p.o. for the first 10 days per-month, or biologically inert placebo.All women will receive 1200 mg of calcium carbonate and 800 IU of vitamin D, daily. Follow-up procedure All patients will be evaluated by a rheumatologist and a reproductive health specialist at baseline,1,2,3,6,9,12,15,18,21, and 24 months. Rheumatic evaluation: 1. General information (baseline). 2. Lupus activity (every visit). 3. Medications: (every visit) Gynecological evaluation: Onset of symptoms since the previous visit using a standardized questionnaire. In addition, a gynecological examination will be performed. Criteria for early termination of the study: A patient will be discontinued from the study whenever any of the following criteria would be present: 1. Development of severe lupus activity (SLEDAI > 30). 2. Development of any putative complication to hormone therapy. 3. Development of any other severe complications due neither to SLE nor hormone therapy. 4. Need prolonged immobilization. Statistical analysis: Between-group comparisons of lupus activity, maximum SLEDAI, and change in SLEDAI score from baseline at each follow-up visit. Incidence-density rates of flares with relative risk and 95 percent confidence intervals.Probability of flares throughout the study using life-table analyses and log-rank test. Climacteric symptoms as the mean value of the Green's scale score at baseline and at each follow-up visit, between-group and intra-group. Bone mineral density as the mean value at baseline, 12 and 24 months, between and intra-group. The proportion of patients in each group who develop secondary effects, as well as the number who quit the study during the follow-up period. Continuous variables will be compared using Student's t-test, and categorical variables using chi-square or Fisher's exact test. Within-group comparisons will be done using the Wilcoxon signed-rank test. P values will be two-sided. Analyses will be conducted by the intention-to-treat method. |
| NCT01148420 ↗ | DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding | Completed | Women's Health Care Clinic, Torrance, California | Phase 4 | 2009-01-01 | The purpose of this study is to investigate the effectiveness and acceptability of high dose MPA (20mg oral 3 times a day) for 3 days combined with an injection of DMPA 150 mg intramuscularly in the treatment of acute heavy, prolonged uterine bleeding who have been identified as being eligible for outpatient management |
| NCT03018249 ↗ | Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer | Completed | NRG Oncology | Early Phase 1 | 2017-10-11 | This randomized surgical window trial evaluates the effect of adding entinostat to medroxyprogesterone acetate before surgery works on progesterone receptors on endometrioid endometrial tumors. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving medroxyprogesterone acetate with or without entinostat may effect tumors from endometrioid endometrial cancer. |
| NCT03018249 ↗ | Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer | Completed | National Cancer Institute (NCI) | Early Phase 1 | 2017-10-11 | This randomized surgical window trial evaluates the effect of adding entinostat to medroxyprogesterone acetate before surgery works on progesterone receptors on endometrioid endometrial tumors. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving medroxyprogesterone acetate with or without entinostat may effect tumors from endometrioid endometrial cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CYCRIN
Condition Name
| Condition Name for CYCRIN | |
| Intervention | Trials |
| FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | 1 |
| FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | 1 |
| FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma | 1 |
| Grade 1 Endometrial Endometrioid Adenocarcinoma | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for CYCRIN
Trials by Country
Clinical Trial Progress for CYCRIN
Clinical Trial Phase
Clinical Trial Sponsors for CYCRIN
Sponsor Name
